Immunovant Stock Analysis

IMVT -  USA Stock  

USD 6.65  0.11  1.63%

The newest Immunovant price drop may raise some interest from private investors. The stock closed today at a share price of 6.65 on 283,172 in trading volume. The company management teams were unable to exploit market volatilities in December. However, diversifying your overall positions with Immunovant can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.64. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Immunovant partners.
Please see Risk vs Return Analysis.

Immunovant Stock Analysis 

 
Refresh
The Immunovant stock analysis report makes it easy to digest most publicly released information about Immunovant and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Immunovant Stock analysis module also helps to analyze the Immunovant price relationship with some important fundamental indicators such as market cap and management efficiency.

Immunovant Stock Analysis Notes

About 65.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunovant recorded a loss per share of 1.27. The entity had not issued any dividends in recent years. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 68 people. To learn more about Immunovant call the company at 917 580 3099 or check out https://immunovant.com.

Immunovant Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunovant's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunovant or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunovant generated a negative expected return over the last 90 days
Immunovant has high historical volatility and very poor performance
Immunovant has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (128.11 M).
Immunovant currently holds about 558.95 M in cash with (86.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86.
Immunovant has a poor financial position based on the latest SEC disclosures
Roughly 65.0% of the company shares are held by company insiders
Latest headline from www.gurufocus.com: HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update - GuruFocus.com

Immunovant Upcoming and Recent Events

Earnings reports are used by Immunovant to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunovant previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report15th of February 2022
Next Earnings Report7th of June 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of June 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Immunovant Largest EPS Surprises

Earnings surprises can significantly impact Immunovant's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-06-01
2021-03-31-0.338-0.290.04814 
2020-11-12
2020-09-30-0.3043-0.250.054317 
2020-08-12
2020-06-30-0.322-0.38-0.05818 
View All Earnings Estimates

Immunovant SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunovant prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunovant investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunovant specific information freely available to individual and institutional investors to make a timely investment decision.
7th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
5th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
30th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
23rd of November 2021
Entry into a Material Definitive Agreement
View
17th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
5th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
27th of September 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
15th of September 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Immunovant Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunovant is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunovant backward and forwards among themselves. Immunovant's institutional investor refers to the entity that pools money to purchase Immunovant's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Eventide Asset Management LlcCommon SharesM43 M
State Street CorpCommon Shares4.1 M35.7 M
Vanguard Group IncCommon Shares3.7 M32.6 M
Blackrock IncCommon Shares3.2 M28.2 M
Alpine Global Management LlcCommon SharesM26.1 M
Group One Trading LpCall Options1.3 M11.5 M
Two Sigma Investments LpCommon Shares1.1 M9.9 M
Ecor1 Capital LlcCommon Shares1.1 M9.9 M
Note, although Immunovant's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunovant Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 903.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunovant's market, we take the total number of its shares issued and multiply it by Immunovant's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Immunovant Profitablity

Immunovant's profitability indicators refer to fundamental financial ratios that showcase Immunovant's ability to generate income relative to its revenue or operating costs. If, let's say, Immunovant is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunovant's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunovant's profitability requires more research than a typical breakdown of Immunovant's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.31) (0.34) 
Return on Average Equity(0.33) (0.35) 
Return on Invested Capital 50.04  53.99 

Management Efficiency

The entity has return on total asset (ROA) of (15.69) % which means that it has lost $15.69 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (26.28) %, meaning that it created substantial loss on money invested by shareholders. Immunovant management efficiency ratios could be used to measure how well immunovant manages its routine affairs as well as how well it operates its assets and liabilities. Return on Invested Capital is likely to gain to 53.99 in 2022, whereas Return on Average Assets are likely to drop (0.34)  in 2022. Total Liabilities is likely to drop to about 21 M in 2022. Current Liabilities is likely to drop to about 19.2 M in 2022
Last ReportedProjected for 2022
Book Value per Share 5.13  5.54 
Enterprise Value over EBIT(12.65) (13.65) 
Enterprise Value over EBITDA(12.42) (13.40) 
Price to Book Value 3.61  4.71 
Tangible Assets Book Value per Share 5.40  4.36 
Enterprise Value1.3 B1.3 B
Tangible Asset Value474.4 M511.8 M

Technical Drivers

As of the 21st of January, Immunovant retains the market risk adjusted performance of (0.21), and Risk Adjusted Performance of (0.06). Immunovant technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Immunovant, which can be compared to its competitors. Please check out Immunovant coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Immunovant is priced fairly, providing market reflects its last-minute price of 6.65 per share. Given that Immunovant has jensen alpha of (0.26), we strongly advise you to confirm Immunovant's regular market performance to make sure the company can sustain itself at a future point.

Immunovant Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Immunovant price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Immunovant Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunovant insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunovant's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunovant insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hughes Douglas J over a week ago via Macroaxis 
Acquisition by Hughes Douglas J of 71492 shares of Immunovant subject to Rule 16b-3
Barnett Eva Renee over a week ago via Macroaxis 
Sale by Barnett Eva Renee of 29959 shares of Immunovant
Macias William L over a week ago via Macroaxis 
Sale by Macias William L of 26813 shares of Immunovant
Macias William L over two months ago via Macroaxis 
Acquisition by Macias William L of 167325 shares of Immunovant subject to Rule 16b-3
Barnett Eva Renee over three months ago via Macroaxis 
Acquisition by Barnett Eva Renee of 333000 shares of Immunovant subject to Rule 16b-3
Macias William L over three months ago via Macroaxis 
Acquisition by Macias William L of 369320 shares of Immunovant subject to Rule 16b-3
Jain Rita over three months ago via Macroaxis 
Acquisition by Jain Rita of 109365 shares of Immunovant subject to Rule 16b-3
Barnett Eva Renee over three months ago via Macroaxis 
Acquisition by Barnett Eva Renee of 59500 shares of Immunovant subject to Rule 16b-3
Macias William L over three months ago via Macroaxis 
Disposition of 369320 shares by Macias William L of Immunovant subject to Rule 16b-3
Salzmann Peter over three months ago via Macroaxis 
Disposition of 464700 shares by Salzmann Peter of Immunovant subject to Rule 16b-3
Hughes Douglas J over three months ago via Macroaxis 
Purchase by Hughes Douglas J of 18247 shares of Immunovant
Migausky George V over three months ago via Macroaxis 
Purchase by Migausky George V of 7000 shares of Immunovant

Immunovant Predictive Daily Indicators

Immunovant intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunovant stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Immunovant Forecast Models

Immunovant time-series forecasting models is one of many Immunovant's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunovant's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Immunovant Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunovant stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunovant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Immunovant. By using and applying Immunovant Stock analysis, traders can create a robust methodology for identifying Immunovant entry and exit points for their positions.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 68 people.

Current Immunovant Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunovant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunovant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
13.0Buy7Odds
Immunovant current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunovant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunovant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunovant, talking to its executives and customers, or listening to Immunovant conference calls.
Immunovant Analyst Advice Details

Immunovant Stock Analysis Indicators

Immunovant stock analysis indicators help investors evaluate how Immunovant stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunovant shares will generate the highest return on investment. By understating and applying Immunovant stock analysis, traders can identify Immunovant position entry and exit signals to maximize returns.
Quick Ratio19.69
Fifty Two Week Low6.68
Shares Short Prior Month3.31M
Average Daily Volume Last 10 Day857.61k
Average Daily Volume In Three Month653.23k
Shares Percent Shares Out2.80%
Short Percent Of Float5.49%
Forward Price Earnings-5.10
Float Shares41.34M
Fifty Two Week High45.94
Enterprise Value To Ebitda-3.19
Fifty Day Average8.00
Two Hundred Day Average10.24
Please see Risk vs Return Analysis. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Is Immunovant's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunovant. If investors know Immunovant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunovant listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.